版本:
中国

BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis

Nov 21 Oragenics Inc :

* U.S. FDA grants fast track designation for the development of Oragenics' AG013 for oral mucositis

* Oragenics - expects to file an Investigational New Drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐